Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Index Funds median (375 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 15 Dec 2022 – 20 Aug 2026, limited by ICICI Prudential Nifty Pharma Index Fund. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one.
View as table
| Date | ICICI Prudential Nifty Pharma Index Fund | Nifty 500 |
|---|---|---|
| 15 Dec 2022 | ₹100.00 | ₹100.00 |
| 06 Apr 2023 | ₹95.98 | ₹93.51 |
| 27 Jul 2023 | ₹116.18 | ₹107.19 |
| 16 Nov 2023 | ₹121.57 | ₹111.46 |
| 07 Mar 2024 | ₹149.08 | ₹129.47 |
| 27 Jun 2024 | ₹151.08 | ₹142.79 |
| 17 Oct 2024 | ₹180.24 | ₹148.11 |
| 06 Feb 2025 | ₹170.81 | ₹137.31 |
| 29 May 2025 | ₹167.47 | ₹144.84 |
| 18 Sep 2025 | ₹175.63 | ₹149.01 |
| 08 Jan 2026 | ₹178.46 | ₹150.03 |
| 30 Apr 2026 | ₹180.93 | ₹143.71 |
| 20 Aug 2026 | ₹205.80 | ₹148.97 |
| Metric | ICICI Prudential · Direct NAV ₹20.46 Very High risk ★★★★★ | Category median Index Funds · 375 funds |
|---|---|---|
| +20.29% | +5.66% | |
| +20.03% | +8.82% | |
| — | +9.15% | |
| — | +11.72% | |
| +21.67% | +7.67% | |
| +20.29% | — | |
| +22.32% | +12.67% | |
| — | +13.64% | |
| — | +12.84% | |
| Risk | ||
| 15.04% | 13.97% | |
| 0.90 | 0.24 | |
| 1.30 | 0.36 | |
| -16.59% | -16.12% | |
| Nifty 500 | — | |
| +9.84% | +0.84% | |
| 0.67 | 1.00 | |
| 108.0% | 102.2% | |
| 61.1% | 97.2% | |
| 0.52% | 0.36% | |
| ₹121.63Cr | ₹177.09Cr | |
| None | — | |
| None | — | |
| ₹1.00K | — | |
| ₹1.00K | — | |
| 26% | 35% | |
| Ashwini Shinde | — | |
| 15 Dec 2022 | — | |
| 20 | — | |
| 78.0% | — | |
| 0.1% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.